Ultime notizie per Charles River (NYSE:CRL) Azioni

Charles River

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Charles River Laboratories International, Inc. Common Stock

Charles River Laboratories International Inc

Cresco Labs Inc

CARDINAL ENERGY LTD ORD by Cardinal Energy Ltd.

Cardinal Energy Ltd

CIRCUIT RESEARCH LABS INC by Circuit Research Labs, Inc.

Circuit Research Labs Inc

CENTRAL PRKNG F/T 5.25PFD by Central Parking Finance Trust

Central Parking Financial Trust

Cerillion PLC

Charles River Laboratories International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>)&nbsp;reported third-quarter 2024 revenue of $1.01 billion on Wednesday, a decrease of 1.6% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $976.02 million</a>.
The impact of foreign currency translation benefited reported revenue by 0.4%, and an acquisition contributed 0.9% to consolidated third-quarter revenue.
A divestiture of a small Safety Assessment site reduced reported revenue by 0.2%. Organic&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41769778/charles-river-laboratories-announces-third-quarter-2024-results" rel="noreferrer noopener">revenue decreased by 2.7%</a>.&nbsp;
In the third quarter of 2024, the operating margin decreased to 11.6% from 14.8% a year ago, primarily driven by costs associated with the company's restructuring initiatives.
The company says the adjusted operating margin improved in all three segments; however, the improvements were more than offset by higher unallocated corporate costs, which resulted in the third-quarter operating margin decreasing to 19.9% from 20.5%.
The company reported adjusted EPS of $2.59, down from $2.72 a year ago, surpassing the consensus estimate of $2.43.
James Foster, Chair, President and CEO, said, "Forward-looking demand indicators were relatively stable in the third quarter, contributing to third-quarter financial performance which exceeded our prior outlook. We are continuing to navigate through a challenging period as global biopharmaceutical clients reduce spending in conjunction with major restructuring and pipeline reprioritization activities, but overall demand trends do not appear to have deteriorated further. In addition, biotech funding has improved in 2024, and demand appears to be demonstrating early signs of stabilization. These factors resulted in a slight, sequential improvement in net book-to-bill and the cancellation rate in the Safety Assessment business."
Revenue for the Discovery and Safety Assessment segment was $615.1 million, down 7.4%. Organic revenue decreased by 7.4%, driven primarily by lower sales volume in the Discovery Services and Safety Assessment businesses.
Research Models and Services&nbsp;sales increased 5.9% to $197.8 million.
Guidance: Charles River Laboratories expects 2024 revenue to decline 3.0%-2.0% on a reported basis and 4.0%–3.0% organically, compared to <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40222523/charles-river-laboratories-stock-sinks-as-it-warns-of-continued-biotech-demand-slump-lowers-forecas" rel="noreferrer noopener">prior decline guidance</a> of 4.5%–2.5% and 5.0%–3.0%, respectively.
The company expects 2024 adjusted EPS of $10.10–$10.30 compared to prior guidance of $9.90–$10.20 and the consensus of $10.
Price Action: At last check on Wednesday, CRL stock was up 14% at $215.10.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41777466/cvs-health-stock-jumps-after-mixed-q3-earnings-takes-1-2-billion-restructuring-charges-hit" target="_blank" rel="noreferrer noopener">CVS Health Stock Jumps After Mixed Q3 Earnings, Takes $1.2 Billion Restructuring Charges Hit</a></li>
</ul>

Earnings

News

Guidance

Health Care

Movers

General

Charles River Q3 Earnings: CEO Notes Improved Biotech Funding And Stabilizing Demand - Here's Why

The S&amp;P 500 and Dow Jones Industrial Average surged to record levels on Wednesday after Donald Trump was elected as <a href="https://www.benzinga.com/topic/donald-trump">the 47th U.S. president.</a>
In Congress, Republicans clinched a majority in the Senate, while the House race remains close. As of Wednesday morning&#8217;s tabulations, Republicans held 198 seats versus 180 for Democrats.
The S&amp;P 500 index, as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), climbed 2% to 5,900 points, while the Dow soared over 3% to 43,500 points. The blue-chip index, monitored through the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), marked its biggest single-day gain since November 2022.
The financials and industrials sectors were the top performers, up 5.2% and 3%, respectively.
The tech-heavy Nasdaq 100 witnessed smaller gains, up 1.8%, while small-cap stocks skyrocketed, with the Russell 2000 index spiking over 5%. 
The CBOE Volatility Index (VIX), often called the &#8220;fear gauge,&#8221; plummeted 22%, indicating waning investor concerns amid post-election optimism.
Investors are responding positively to the prospect of more lenient tax policies under the upcoming Trump administration, though inflation risks and potential shifts in Federal Reserve policy highlighted by economists seem to be largely overlooked by the market for now.
<h3 class="wp-block-heading">Economic Implications Of A Trump Presidency, Goldman Sachs Weighs In</h3>
&#8220;If Republicans secure a narrow House majority, this would likely enable a full extension of the 2017 tax cuts, set to expire in 2025, potentially with some reinstated business investment incentives,&#8221; wrote Jan Hatzius, Goldman Sachs&#8217; chief economist.
A Republican-controlled Congress may also drive increased federal spending, particularly on defense, Goldman Sachs indicated.
"We would expect Trump to impose additional tariffs averaging 20% on imports from China," Hatzius added, highlighting that this policy could provide a &#8220;one-time boost to core PCE inflation&#8221; and &#8220;a modest drag on GDP.&#8221;
Goldman Sachs projects that the incoming Trump administration would likely pursue a more relaxed approach to regulation, especially in energy, financial services, and labor. 
However, while antitrust oversight may soften somewhat, scrutiny of the tech sector is expected to persist.
<h3 class="wp-block-heading">Top-Performing S&amp;P 500 Sectors After Trump Secures Election Victory</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Sector</th>
<th>ETF</th>
<th>1-day Change (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Financials</td>
<td>Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>5.15%</td>
</tr>
<tr>
<td>Industrials</td>
<td>Industrial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>2.99%</td>
</tr>
<tr>
<td>Energy</td>
<td>Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>2.68%</td>
</tr>
<tr>
<td>Consumer Discretionary</td>
<td>Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>2.60%</td>
</tr>
<tr>
<td>Technology</td>
<td>Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>2.22%</td>
</tr>
<tr>
<td>Materials</td>
<td>Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>1.66%</td>
</tr>
<tr>
<td>Communications</td>
<td>Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>1.54%</td>
</tr>
<tr>
<td>Health Care</td>
<td>Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>1.08%</td>
</tr>
<tr>
<td>Consumer Staples</td>
<td>Consumer Staples Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>-0.42%</td>
</tr>
<tr>
<td>Utilities</td>
<td>Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>-1.23%</td>
</tr>
<tr>
<td>Real Estate</td>
<td>Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>-1.29%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 9.45 a.m. ET</figcaption></figure>
<h3 class="wp-block-heading">Top Gainers, Losers Within The S&amp;P 500 Following Trump&#8217;s Win</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Last</th>
<th>Chg %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>)</td>
<td>187.37</td>
<td>23.39%</td>
</tr>
<tr>
<td>Capital One Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>)</td>
<td>193.69</td>
<td>16.64%</td>
</tr>
<tr>
<td>Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>)</td>
<td>65.93</td>
<td>16.03%</td>
</tr>
<tr>
<td>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>288.40</td>
<td>14.70%</td>
</tr>
<tr>
<td>Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>)</td>
<td>164.96</td>
<td>14.07%</td>
</tr>
<tr>
<td>Trimble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NASDAQ">TRMB</a>)</td>
<td>69.97</td>
<td>13.55%</td>
</tr>
<tr>
<td>Charles River Laboratories International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>)</td>
<td>214.16</td>
<td>13.51%</td>
</tr>
<tr>
<td>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>62.76</td>
<td>13.40%</td>
</tr>
<tr>
<td>Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>)</td>
<td>72.43</td>
<td>13.05%</td>
</tr>
<tr>
<td>Steel Dynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>)</td>
<td>149.73</td>
<td>10.38%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 9.45 a.m. ET</figcaption></figure>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Last</th>
<th>Chg %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)</td>
<td>21.01</td>
<td>-24.15%</td>
</tr>
<tr>
<td>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>74.05</td>
<td>-17.67%</td>
</tr>
<tr>
<td>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>)</td>
<td>181.42</td>
<td>-15.97%</td>
</tr>
<tr>
<td>D.R. Horton, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>)</td>
<td>161.70</td>
<td>-6.68%</td>
</tr>
<tr>
<td>The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>)</td>
<td>14.50</td>
<td>-6.51%</td>
</tr>
<tr>
<td>Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>)</td>
<td>166.31</td>
<td>-6.19%</td>
</tr>
<tr>
<td>Universal Health Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>)</td>
<td>199.41</td>
<td>-6.01%</td>
</tr>
<tr>
<td>Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)</td>
<td>87.26</td>
<td>-6.01%</td>
</tr>
<tr>
<td>American Tower Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>)</td>
<td>201.33</td>
<td>-5.86%</td>
</tr>
<tr>
<td>Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>)</td>
<td>63.15</td>
<td>-5.42%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 9.45 a.m. ET</figcaption></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">Trump&#8217;s Historic Return: 7 Ways His Second Term Could Impact The US Economy</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Large Cap

Sector ETFs

Broad U.S. Equity ETFs

Federal Reserve

Tech

ETFs

SPDR Dow Jones Industrial Average ETF Trust

DLTR

ENPH

FSLR

SMCI

STLD

TRMB

TSLA

XLRE

Select Sector SPDR-Consumer Discretionary

S&P 500, Dow Hit Record Highs After Trump Win; Fear Index Drops 20%

WIIM

Charles River Laboratories shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 outlook.

Charles River Laboratories Raises FY24 Outlook: Sees Adjusted EPS Of $10.10–$10.30 Vs. $10 Estimate (Prior View: $9.90–$10.20)

Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) reported quarterly earnings of $2.59 per share which beat the analyst consensus estimate of $2.43 by 6.58 percent. The company reported quarterly sales of $1.009 billion which beat the analyst consensus estimate of $976.015 million by 3.38 percent. This is a 1.75 percent decrease over sales of $1.027 billion the same period last year.

Earnings Beats

Charles River Q3 2024 Adj. EPS $2.59 Beats $2.43 Estimate, Sales $1.009B Beat $976.015M Estimate

In the current market session, Charles River Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) share price is at $184.00, after a 0.70% spike. Moreover, over the past month, the stock fell by 7.83%, but in the past year, spiked by 11.10%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1729878464_0.png" alt="Past Year Chart" />

<h3>How Does Charles River P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Charles River has a lower P/E than the aggregate P/E of 45.48 of the Life Sciences Tools &amp; Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1729878464_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Charles River

Investors with significant funds have taken a bullish position in Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in CRL usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 9 options transactions for Charles River. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 44% being bullish and 44% bearish. Of all the options we discovered, 8 are puts, valued at $362,386, and there was a single call, worth $39,225.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $180.0 and $190.0 for Charles River, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Charles River's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Charles River's whale activity within a strike price range from $180.0 to $190.0 in the last 30 days. 
<h3>Charles River 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729798244_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$9.3</td>
<td>$9.2</td>
<td>$9.2</td>
<td>$180.00</td>
<td>$102.1K</td>
<td style="text-align: right;">323</td>
<td style="text-align: right;">162</td>
</tr>
<tr>
<td>CRL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$9.9</td>
<td>$9.8</td>
<td>$9.8</td>
<td>$180.00</td>
<td>$48.0K</td>
<td style="text-align: right;">323</td>
<td style="text-align: right;">279</td>
</tr>
<tr>
<td>CRL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$9.5</td>
<td>$9.5</td>
<td>$9.5</td>
<td>$180.00</td>
<td>$42.7K</td>
<td style="text-align: right;">323</td>
<td style="text-align: right;">209</td>
</tr>
<tr>
<td>CRL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$7.7</td>
<td>$7.4</td>
<td>$7.4</td>
<td>$190.00</td>
<td>$39.2K</td>
<td style="text-align: right;">189</td>
<td style="text-align: right;">644</td>
</tr>
<tr>
<td>CRL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$12.4</td>
<td>$12.0</td>
<td>$12.4</td>
<td>$185.00</td>
<td>$37.2K</td>
<td style="text-align: right;">40</td>
<td style="text-align: right;">344</td>
</tr>
</tbody>
</table>

<h3>About Charles River</h3>
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model &amp; services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery &amp; safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Having examined the options trading patterns of Charles River, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Charles River</h3>
<ul>
<li>Currently trading with a volume of 735,960, the CRL's price is down by -0.34%, now at $185.99. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 13 days.</li>
</ul>
<h3>What Analysts Are Saying About Charles River</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $179.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from CLSA has revised its rating downward to Underperform, adjusting the price target to $167. 
&#x2A; Reflecting concerns, an analyst from Evercore ISI Group lowers its rating to In-Line with a new price target of $190. 
&#x2A; Reflecting concerns, an analyst from Citigroup lowers its rating to Sell with a new price target of $175. 
&#x2A; Reflecting concerns, an analyst from Redburn Atlantic lowers its rating to Sell with a new price target of $151. 
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Neutral, setting a price target of $215. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Charles River options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

This Is What Whales Are Betting On Charles River

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B. Riley Securities analyst Hal Goetsch initiated coverage on Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Neutral rating and announced a price target of $185. Coinbase shares closed at $210.72 on Tuesday. <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>CLSA initiated coverage on Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with an Underperform rating and announced a price target of $167. Charles River shares closed at $185.94 on Tuesday. <a href="https://www.benzinga.com/quote/CRL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Patrick Cunningham initiated coverage on FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) with a Neutral rating and announced a price target of $67. FMC shares closed at $62.38 on Tuesday. <a href="https://www.benzinga.com/quote/FMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Daiwa Capital initiates coverage on Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) with an Outperform rating and announced a price target of $4.6. Grab shares closed at $4.16 on Tuesday. <a href="https://www.benzinga.com/quote/GRAB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer initiated coverage on Ferguson Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with an Outperform rating and announced a price target of $234. Ferguson shares closed at $195.99 on Tuesday. <a href="https://www.benzinga.com/quote/FERG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read More:<a href="https://www.benzinga.com/news/earnings/24/10/41479244/dow-edges-lower-as-investors-watch-earnings-reports-with-caution-fear-index-remains-in-greed-zone"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41479244/dow-edges-lower-as-investors-watch-earnings-reports-with-caution-fear-index-remains-in-greed-zone">Dow Edges Lower As Investors Watch Earnings Reports With Caution: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Initiation

Pre-Market Outlook

Analyst Ratings

Trading Ideas

COIN

FERG

GRAB

This Ferguson Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

CLSA initiates coverage on Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Underperform rating and announces Price Target of $167.

Price Target

CLSA Initiates Coverage On Charles River with Underperform Rating, Announces Price Target of $167

Redburn Atlantic analyst Jamie Clark initiates coverage on Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Sell rating and announces Price Target of $151.

Redburn Atlantic Initiates Coverage On Charles River with Sell Rating, Announces Price Target of $151

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Bernstein analyst Bokyung Suh upgraded the rating for Coupang, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) from Underperform to Outperform and announced a $30 price target. Coupang shares gained 1.9% to close at $24.59 on Friday. <a href="https://www.benzinga.com/quote/CPNG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie analyst Ellie Jiang upgraded the rating for Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) from Neutral to Outperform. Alibaba shares gained 1.5% to close at $114.53 on Friday. <a href="https://www.benzinga.com/quote/BABA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie analyst Ellie Jiang upgraded PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) from Neutral to Outperform and boosted the price target from $126 to $224. PDD shares gained 1.1% to close at $154.27 on Friday. <a href="https://www.benzinga.com/quote/PDD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Matt Farrell upgraded the rating for Netflix, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from Neutral to Overweight and raised the price target from $650 to $800. Netflix shares gained 1.8% to close at $719.70 on Friday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group analyst Stephen Richardson upgraded Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) from In-Line to Outperform and boosted the price target from $305 to $365. Air Products shares slipped 0.03% to close at $285.50 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying BABA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="510" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07081105/image-35-1024x510.png" alt="" class="wp-image-583258" style="width:610px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07081105/image-35-1024x510.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07081105/image-35-300x149.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07081105/image-35-768x383.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07081105/image-35.png 1351w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41196046/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yiel">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Upgrades

BABA

CPNG

NFLX

Citigourp Global Markets 2% Protected Notes Linked To The Djia

This Alibaba Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d11d3db85e93000188d7b6/alexia-howard">Bernstein analyst Alexia Howard</a> downgraded the rating for The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) from Outperform to Market Perform and lowered the price target from $230 to $205. Hershey shares gained 0.5% to close at $191.84 on Friday. <a href="https://www.benzinga.com/quote/HSY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Aleksey Yefremov downgraded the rating for Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Overweight to Sector Weight. Celanese shares gained 2.1% to close at $136.67 on Friday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586e4053351b9b00018bee9e/kannan-venkateshwar">Barclays analyst Kannan Venkateshwar </a>downgraded the rating for Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from Equal-Weight to Underweight and maintained the price target of $550. Netflix shares gained 1.8% to close at $719.70 on Friday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Bryan Spillane downgraded Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) from Buy to Neutral and slashed the price target from $300 to $255. Constellation shares gained 1.2% to close at $246.67 on Friday. <a href="https://www.benzinga.com/quote/STZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group analyst Ross Muken downgraded the rating for Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Outperform to In-Line and cut the price target from $225 to $190. Charles River shares gained 0.6% to close at $190.74 on Friday. <a href="https://www.benzinga.com/quote/CRL/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NFLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="512" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07080259/image-34-1024x512.png" alt="" class="wp-image-583229" style="width:568px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07080259/image-34-1024x512.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07080259/image-34-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07080259/image-34-768x384.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07080259/image-34.png 1333w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41196046/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yiel">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Downgrades

This Netflix Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

In the preceding three months, 12 analysts have released ratings for Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Charles River, presenting an average target of $211.08, a high estimate of $250.00, and a low estimate of $175.00. This current average represents a 14.54% decrease from the previous average price target of $247.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1728302429_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Charles River. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$190.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$175.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$191.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$203.00</td>
<td>$228.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$210.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$240.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$250.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$191.00</td>
<td>$239.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$239.00</td>
<td>$271.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Charles River. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Charles River compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Charles River's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CRL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Charles River analyst ratings.</a>
<h2>Get to Know Charles River Better</h2>
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model &amp; services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery &amp; safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
<h3>Charles River: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Charles River's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -3.19%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Charles River's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.77%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.44%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Charles River's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.12%, the company showcases efficient use of assets and strong financial health.
Debt Management: Charles River's debt-to-equity ratio is below the industry average at 0.76, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Charles River: Insights From 12 Financial Analysts

Evercore ISI Group analyst Ross Muken downgrades Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Outperform to In-Line and lowers the price target from $225 to $190.

Evercore ISI Group Downgrades Charles River to In-Line, Lowers Price Target to $190

Charles River And Lundbeck Partner To Use AI-Powered Logica Platform For Advancing Neurological Disease Drug Discovery

B of A Securities analyst Derik De Bruin downgrades Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Buy to Neutral and lowers the price target from $250 to $215.

B of A Securities Downgrades Charles River to Neutral, Lowers Price Target to $215

Citigroup analyst Patrick Donnelly downgrades Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Neutral to Sell and lowers the price target from $215 to $175.

Citigroup Downgrades Charles River to Sell, Lowers Price Target to $175

FBLG

Fibrobiologics Says On Sept 19, Entered Into A Master Services Agreement With Charles River Laboratories; Agreement Term Expires On Sept 19, 2029, Unless Earlier Terminated By Either Party In Accordance With Agreement

Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $218.3, with a high estimate of $250.00 and a low estimate of $190.00. Observing a downward trend, the current average is 13.6% lower than the prior average price target of $252.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1726833616_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Charles River by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$191.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$203.00</td>
<td>$228.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$210.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$240.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$250.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$191.00</td>
<td>$239.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$239.00</td>
<td>$271.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$230.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Charles River. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Charles River compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Charles River's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Charles River's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CRL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Charles River analyst ratings.</a>
<h2>Get to Know Charles River Better</h2>
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model &amp; services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery &amp; safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
<h3>Charles River: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Charles River's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -3.19%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Charles River's net margin excels beyond industry benchmarks, reaching 8.77%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Charles River's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.44%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.12%, the company showcases effective utilization of assets.
Debt Management: Charles River's debt-to-equity ratio is below the industry average at 0.76, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Charles River In The Eyes Of 10 Experts

Baird analyst Eric Coldwell maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Neutral and lowers the price target from $191 to $190.

Baird Maintains Neutral on Charles River, Lowers Price Target to $190

Charles River cut to in line by Evercore on weakening demand

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Penumbra (PEN – Research Report), Nurix Therapeutics (NRIX – Rese...

Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Nurix Therapeutics (NRIX) and Charles River Labs (CRL)

CLSA initiated coverage of Charles River (CRL) with an Underperform rating and $167 price target Published first on TheFly – the ultimate source fo...

Charles River initiated with an Underperform at CLSA

ICON leads a selloff among CROs after guidance cut; Baird downgrades

SkyTaxi, a charter company working for Charles River (CRL), was recently fined C$7,500 by Canadian authorities for improperly shipping long-tailed ...

Charles River shipments of research monkeys spark investigation, STAT says

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: McDonald's (MCD) reported upbeat Q3 re...

McDonald's, Ford, Pfizer report Q3 earnings beats: Morning Buzz

Here's the major earnings before the open tomorrow

Charles River Laboratories Non-GAAP EPS of $2.59 beats by $0.17, revenue of $1.01B beats by $34.5M

Reports Q3 revenue $1.01B, consensus $976.01M. James Foster, chair, president and CEO, said, "Forward-looking demand indicators were relatively sta...

Charles River reports Q3 adjusted EPS $2.59, consensus $2.43

Notable gainers among liquid option names this morning include Discover (DFS) $181.20 +29.35, Synchrony (SYF) $65.84 +9.02, Capital One (COF) $189....

Early notable gainers among liquid option names on November 6th

AAPL

ABUS

ADRNY

ATHM

AUDC

BMWYY

CELH

CLBT

CNDT

CROX

EHTH

ENOV

ESLOY

FFIV

FOLD

HENKY

HLIT

ICLR

IONS

IPGP

LKNCY

LNTH

MCFT

MKTX

MOGO

NEON

NRIX

OESX

OPRA

PERI

PFGC

PRGO

PYPL

RPRX

SNDR

SOFI

STWD

TCPC

TEVA

TMDX

URGN

VONOY

VRNOF

Legal

Press Releases

CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary Duties

Charles River Laboratories to Present at Baird and Morgan Stanley Conferences

Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience

Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research

Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease

Charles River Provides Translational Expertise at Neuroscience 2024

Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call

Charles River Launches New Retrogenix® Non-Human Protein Library

Charles River Laboratories Announces Third-Quarter 2024 Results

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Charles River

Notizie

Ultime notizie per Charles River (NYSE:CRL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO